DUBLIN--(BUSINESS WIRE)--The "PPAR-Beta / Delta Agonist -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. PPAR-Beta / Delta Agonist - Pipeline Insight, 2019 ...
Intrigued by results from a 13-patient, phase II pilot study with peroxisome proliferator-activated receptor (PPAR) delta agonist MBX-8025 for homozygous familial hypercholesterolemia (HoFH), Cymabay ...
CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant ...
Providence, RI – Stimulation of a receptor in the brain that controls insulin responses has been shown to halt or diminish the neurodegeneration of Alzheimer's disease, providing evidence that the ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- The ...
Inventiva’s nonalcoholic steatohepatitis (NASH) prospect beat placebo at cutting liver inflammation in patients with NASH without making their scarring worse, hitting its primary endpoint in a phase ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE ...
Farmingham, CT - A new mouse study published this week provides some insight into understanding why rofecoxib (Vioxx, Merck) and the other cyclooxygenase (COX)-2 inhibitors increase the risk of ...
Riding the wave of a phase 2 win, Inventiva is gearing up for its U.S. IPO. The French biotech filed to raise up to $90 million in its Nasdaq debut, which will push its lead program into a phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback